Evidence map›Paper›PMID 36359762›Full record

ReviewCells2022

Mesenchymal Stem Cell-Derived Extracellular Vesicles for Therapeutic Use and in Bioengineering Applications.

Caroline McLaughlin, Pallab Datta, Yogendra P Singh, Alexis Lo, Summer Horchler, Irina A Elcheva, Ibrahim T Ozbolat, Dino J Ravnic, Srinivas V Koduru

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Caroline McLaughlinDepartment of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.ORCID 0000-0003-1593-3121
Pallab DattaDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, West Bengal 700054, India.
Yogendra P SinghDepartment of Biomedical Engineering, Materials Research Institute, The Huck Institutes of Life Sciences, Penn State University, University Park, PA 16802, USA.ORCID 0000-0003-4941-9323
Alexis LoDepartment of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
Summer HorchlerDepartment of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
Irina A ElchevaDepartment of Pediatrics, Hematology/Oncology, Penn State College of Medicine, Hershey, PA 17033, USA.ORCID 0000-0002-3992-2817
Ibrahim T OzbolatDepartment of Biomedical Engineering, Materials Research Institute, The Huck Institutes of Life Sciences, Penn State University, University Park, PA 16802, USA.ORCID 0000-0001-8328-4528
Dino J RavnicDepartment of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
Srinivas V KoduruDepartment of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.ORCID 0000-0001-6827-2908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are small lipid bilayer-delimited particles that are naturally released from cells into body fluids, and therefore can travel and convey regulatory functions in the distal parts of the body. EVs can transmit paracrine signaling by carrying over cytokines, chemokines, growth factors, interleukins (ILs), transcription factors, and nucleic acids such as DNA, mRNAs, microRNAs, piRNAs, lncRNAs, sn/snoRNAs, mtRNAs and circRNAs; these EVs travel to predecided destinations to perform their functions. While mesenchymal stem cells (MSCs) have been shown to improve healing and facilitate treatments of various diseases, the allogenic use of these cells is often accompanied by serious adverse effects after transplantation. MSC-produced EVs are less immunogenic and can serve as an alternative to cellular therapies by transmitting signaling or delivering biomaterials to diseased areas of the body. This review article is focused on understanding the properties of EVs derived from different types of MSCs and MSC-EV-based therapeutic options. The potential of modern technologies such as 3D bioprinting to advance EV-based therapies is also discussed.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsMicroRNAsBioengineeringCell- and Tissue-Based TherapyMicroRNAsbiomarkersbioprintingEVsextracellular vesiclesMSCsstem cells

Identifiers

PMID36359762
PMCPMC9657427

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.